Recombinant antibodies and their derivatives are increasingly being utilized as therapeutic agents. The clinical applications of antibodies often require large quantities of highly purified molecules, sometimes for multiple treatments. Therefore, the development of exceptionally efficient expression systems is crucial to exploit the potential of antibody technology fully. Mammary gland bioreactor technology has emerged as a groundbreaking method for producing therapeutic antibodies.
Types of Antibodies
Mammary gland bioreactor technology supports the production of various types of antibodies, each tailored for specific therapeutic applications. Below are the key types of antibodies that can be efficiently produced using this method.
Monoclonal Antibodies (mAbs)
Monoclonal antibodies are homogenous antibodies that target a single epitope on an antigen. They are commonly used in therapies for cancers, autoimmune diseases, and infectious diseases. Mammary gland bioreactors are well-suited for mAb production due to their ability to produce high-yield and structurally intact antibodies in milk.
Fig.1 Expression of anti-PD-1 antibody in the milk of transgenic mice by western blotting. (Gong, G., et al., 2021)
Bispecific Antibodies (bsAbs)
Bispecific antibodies can simultaneously bind two different antigens or epitopes, offering a multifunctional approach to therapy, especially in oncology. The mammary gland bioreactor technology allows for the efficient production of complex bsAbs with the desired functionality and structural accuracy.
Antibody Fragments
Antibody fragments, including Fab, and single-chain variable fragments (scFvs), are smaller, more flexible, and can penetrate tissues more easily than full-length antibodies. Mammary gland bioreactors provide a cost-effective platform for their production at a large scale, making them ideal for applications in diagnostic imaging and therapeutic interventions.
Antibody Development in Mammary Gland Bioreactors
Mammary gland bioreactors offer an innovative platform for the production of therapeutic antibodies, harnessing the inherent protein synthesis and secretion pathways of the mammary gland to yield high-quality antibodies on a large scale. The resulting antibodies exhibit structural similarity to endogenous counterparts, rendering them exceptionally potent for therapeutic applications. The following table presents antibody development in mammary gland bioreactors.
| Antibody Type |
Mammary Gland Bioreactor Model |
Function |
Phase |
| Trastuzumab |
Transgenic Goat |
Targeting HER2 in breast cancer |
I |
| Pembrolizumab |
Transgenic Cow |
PD-1 checkpoint inhibitor for melanoma |
II |
| Infliximab |
Transgenic Rabbit |
TNF-alpha inhibitor for rheumatoid arthritis |
Preclinical |
| Bevacizumab |
Transgenic Sheep |
VEGF inhibitor for anti-angiogenesis |
Preclinical |
| Rituximab |
Transgenic Pig |
Targeting CD20 for B-cell lymphoma |
III |
We specialize in offering comprehensive antibody development services utilizing mammary gland bioreactors at CD BioSciences. Our state-of-the-art transgenic animal models, including mice, goats, cows, rabbits, sheep, and pigs, facilitate the production of a diverse range of therapeutic antibodies. Whether you are looking to develop monoclonal, bispecific, or antibody fragments, our team is here to support your research and development goals. Contact us today to learn how we can assist you in advancing your antibody projects.
Reference
- Gong, G., et al.; (2021). Expression of a recombinant anti-programed cell death 1 antibody in the mammary gland of transgenic mice. Preparative biochemistry & biotechnology, 51(2), 183–190.
Our services are for research use only and cannot be used for any clinical purposes.
Related Solutions
